GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Are iPS Cells Used in Routine Treatment?

Not broadly. iPS-derived cells have entered conditionally approved treatment in Japan, but they are not established routine care across diseases. On March 6, 2026, Japan approved AMCHEPRY for certain Parkinson’s motor symptoms and RiHEART for severe heart failure caused by ischemic cardiomyopathy. These are restricted, time-limited approvals, not approval for general iPS injections or anti-aging treatment. 20260220 001713283.pdf

Approved use, research participation, and an appointment at a particular hospital are different questions. The two Japanese products require surgery, immunosuppression, specialist teams, and post-marketing assessment. Their approvals do not establish that either treatment works for every eligible patient. 000281617.pdf S41586 025 08700 0 000281693.pdf

Are iPS Cells Used in Routine Treatment?

Regulatory sources rechecked October 28, 2026. Availability and individual eligibility must be confirmed with the treating institution.

Which iPS Treatments Have Approval?

Japan granted both products conditional approval for seven years. This pathway allows clinical use while efficacy is further evaluated and safety data continue to accumulate. It requires a subsequent application for standard approval within the designated period; conversion to standard approval is not automatic. 20260220 000281617.pdf 000281693.pdf

Conditional iPS-derived product approvals granted in Japan in March 2026
Product Approved use Cells and procedure Treatment requirements
AMCHEPRY (raguneprocel) Improvement of Parkinson’s motor symptoms inadequately controlled by conventional medicines, including levodopa-containing drugs Donor iPS-derived dopaminergic progenitor cells implanted into both putamina in the brain by stereotactic surgery; approved target dose 5.4 million cells per hemisphere Tacrolimus, generally tapered over 12 weeks starting approximately one year after treatment; experienced Parkinson’s and neurosurgical teams; post-marketing assessment covering treated patients. 000281617.pdf
RiHEART Severe heart failure associated with ischemic cardiomyopathy despite standard treatment, including medicines and invasive interventions Three donor iPS-derived heart-muscle cell sheets, about 100 million cells in total, placed on the heart surface, generally through a left thoracotomy A 90-day course of prednisolone, tacrolimus, and mycophenolate mofetil, including tapering; specialist heart-failure and surgical care; post-marketing assessment covering treated patients. 000281693.pdf

Both products are allogeneic, meaning donor-derived, and contain differentiated cells made from iPS cells. They are not intravenous infusions of undifferentiated iPS cells. Their Japanese indications cannot be extended to another disease or country simply because a clinic uses the term “stem cells.” 000281617.pdf 000281693.pdf

Approval alone does not confirm that a hospital is currently accepting patients. Neither a product listing nor an insurance price establishes an appointment, an overseas patient’s eligibility, or coverage. MHLW’s May 13, 2026 pricing document lists AMCHEPRY at ¥55,306,737 per 18-vial set for scheduled listing on May 20. That is a product price, not an all-inclusive treatment quote. An itemized cost estimate should separately address surgery, hospitalization, medicines, and follow-up. 001699508.pdf

What Does the Human Evidence Show?

Parkinson’s Disease

The Kyoto University phase I/II trial treated seven people aged 50–69 and followed them for 24 months. It was a single-center, open-label study without a control group. Safety was the primary focus; motor scores and dopamine production were secondary outcomes. Six participants were included in the efficacy analysis. S41586 025 08700 0

Four of six improved on the MDS-UPDRS Part III OFF score, a motor assessment performed off medication. The mean reduction was 9.5 points, or 20.4%; five of six improved on the ON-medication score. Putaminal fluorine-18-DOPA PET influx rate constant, a measure related to dopamine synthesis, increased by 44.7%. That scan result is not a 44.7% improvement in symptoms. S41586 025 08700 0

There were 73 adverse-event episodes across the seven participants: 72 mild and one moderate, with no serious adverse events reported. MRI showed no graft overgrowth during follow-up. Six of seven had mild worsening of dyskinesia, or involuntary movements. Most Parkinson’s medication doses were maintained unless adjustment was necessary. Without a control group, the study cannot establish the size of a treatment effect or show that Parkinson’s progression was stopped. Two years also cannot exclude later complications. S41586 025 08700 0

Ischemic Heart Failure

The RiHEART phase I/II study enrolled eight patients in Japan and observed them for 52 weeks. It was open-label, multicenter, and uncontrolled. Its primary efficacy endpoint was improvement in left ventricular ejection fraction, or LVEF, measured by echocardiography at week 26. Two of eight met the prespecified improvement threshold of at least five percentage points above baseline. This is a pumping-function endpoint, not proof of longer survival. 000281693.pdf

Seven of eight patients had adverse events. Ten serious adverse events occurred in five patients, including infection and worsening heart failure; the review report states that a causal relationship to RiHEART was ruled out for those events. It separately reports potentially procedure-related events such as anemia and wound complications, and potentially immunosuppressant-related events including renal dysfunction. These distinctions matter: an event occurring after treatment is not necessarily caused by the cells, but “no serious product-related events” does not mean “no serious events.” 000281693.pdf

Corneal Disease and Spinal Cord Injury

Other human studies remain important research, not evidence of broad routine availability. At Osaka University, four people with limbal stem-cell deficiency received donor iPS-derived corneal epithelial sheets on the eye surface in a first-in-human, single-arm study. Vision improved at one year, and no serious adverse events such as tumor formation or clinical rejection were reported during the two-year observation period. Four treated eyes cannot establish effectiveness for other eye diseases. Nishida2024 11 8

Keio University’s safety-focused clinical study treated four people with complete, subacute spinal cord injury using iPS-derived neural stem/progenitor cell transplants. After one year of observation, one improved from AIS grade A to C and another from A to D; no serious adverse events causally linked to the therapy were reported. This small study was not a randomized comparison, and its findings do not establish benefit for longstanding spinal cord injury. E2443b34e4cb4c3d04da9dc31cb1341b4199a8e390ffe8b572861bc22ddf8e32

Why Does Laboratory Use Not Mean Routine Care?

Induced pluripotent stem cells are adult cells reprogrammed into an embryonic-like state. Researchers can then guide them toward specialized cell types. C124144 Their use in disease models and drug discovery does not involve transplanting those laboratory models into patients. A report that a drug was tested on iPS-derived cells is therefore not a report that someone received an iPS treatment. PMC6584039

For transplantation, manufacturers must control cell identity, purity, potency, and contamination, including residual undifferentiated cells that could form tumors. The approved products have specific manufacturing controls; approval does not mean these checks are unnecessary. 000281617.pdf FDA laboratory research also identifies replication-associated DNA damage as a concern in iPS cells. This is a reason for genomic-quality testing, not a measured cancer rate in treated patients. High replication rate induced pluripotent stems cells appears contribute breaks dna

Surgery, rejection risk, and immunosuppression add treatment burdens. These burdens do not by themselves make a therapy non-routine—many established treatments require specialist care. Here, the more important limitation is that benefits and longer-term safety still need confirmation under the conditional approvals. 20260220 000281693.pdf

Does a Private Clinic Offer Prove Routine Use?

No. An offer of fat-derived cells, bone-marrow cells, platelet-rich plasma, or cell-free exosomes is not interchangeable with either approved iPS-derived product. The FDA’s consumer alert warns about unapproved regenerative products and states that no exosome products are FDA-approved. That is a US regulatory statement, not a ruling on every Japanese service. Consumer alert regenerative medicine products including stem cells and exosomes

Japan also has a separate provision-plan framework under the Act on the Safety of Regenerative Medicine. Required committee review and submission of a plan are not the same as marketing authorization for a named product. A filing number is not proof of clinical benefit. The site’s explanation of regenerative medicine registration and product approval covers this distinction; the separate regulatory frameworks are described by PMDA. 000250262.pdf

Nor is registration alone enough to validate an experimental offer. A study record must be checked against the actual institution, investigators, protocol, recruitment status, and ethics and regulatory requirements. It is not evidence that the intervention works.

What Should You Check Before Seeking Treatment?

Consider a hypothetical offer of an “iPS infusion” for Parkinson’s disease. The word “iPS” is not enough: AMCHEPRY’s reviewed method is stereotactic transplantation into the brain, not an intravenous infusion. If the route, product, or indication differs, ask the treating institution to explain its regulatory basis rather than assuming the approval applies. 000281617.pdf

Ask your neurologist, cardiologist, or relevant specialist to review the following before you travel or pay:

  • Product and cells: the exact product name, cell source, differentiated cell type, dose, and administration route.
  • Regulatory route: the approved indication and authorization, or the research protocol, registration, and applicable approvals. Do not substitute a clinic’s general registration for these details.
  • Institution and eligibility: the named treating hospital, responsible clinician, current patient intake, inclusion criteria, and post-treatment monitoring. Verify the hospital’s qualifications and treatment arrangements directly.
  • Benefits, harms, and alternatives: the evidence for your condition, surgical and immune risks, established alternatives, total costs, and who manages complications after you return home.

For research options, the guide to finding stem cell clinical trials in Japan explains where to look. Participation requires the study team’s assessment; a listing is neither a treatment recommendation nor guaranteed access. Do not stop prescribed treatment or delay established care while exploring an experimental option.

For questions about this website’s treatment information, contact the patient support team. An enquiry is not an iPS treatment booking or a medical eligibility assessment.

Contact Patient Support

When Could iPS Treatment Become Routine?

That must be assessed product by product and indication by indication. Confirmatory evidence, longer-term safety data, regulatory decisions, and reliable clinical delivery could support wider use. Standard approval would not automatically make a treatment available at every hospital, and routine use for one disease would not require approval for unrelated diseases. 20260220

For patients today, the answer is restricted clinical use, not broad routine treatment. Japan’s conditional approvals are a real step beyond research-only access. They do not validate a different cell product, an unrelated indication, or a clinic’s generic promise of an iPS injection.

Disclosure: This website is operated by an independent patient support team providing information and appointment enquiries relating to GINZA NOA CLINIC. Its commercial role does not establish medical expertise or independent evidence of benefit. This article is general information, not personal medical advice or a clinical eligibility assessment.